Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RECQL | P46063 | 1/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.56 |
| ▸ | TSHR | P16473 | 1/20 | 0.52 |
| ▸ | CCR3 | P51677 | 1/20 | 0.50 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | DRD2 | P14416 | 1/20 | 0.49 |
| ▸ | DRD4 | P21917 | 1/20 | 0.49 |
| ▸ | DRD3 | P35462 | 1/20 | 0.49 |
| ▸ | ACHE | P22303 | 2/20 | 0.49 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.48 |
| ▸ | MC4R | P32245 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4062103 | 0.85 | RECQL (0.60) | RECQLSMN1; SMN2TSHRCCR3SIGMAR1 | |
| SCHEMBL3709310 | 0.83 | RECQL (0.70) | RECQLSMN1; SMN2TSHRCCR3SIGMAR1 | |
| Hydrochloric Acid SCHEMBL3706762 | 0.82 | RECQL (0.68) | RECQLSMN1; SMN2TSHRCCR3SIGMAR1 | |
| SCHEMBL3956954 | 0.81 | MC4R (0.69) | RECQLSMN1; SMN2TSHRCCR3MAPT | |
| SCHEMBL13432148 | 0.81 | MC4R (0.69) | RECQLSMN1; SMN2TSHRSIGMAR1DRD2 | |
| SCHEMBL3017800 | 0.81 | ACHE (0.55) | RECQLSMN1; SMN2TSHRSIGMAR1ACHE | |
| SCHEMBL8997893 | 0.80 | CCR3 (0.56) | CCR3SIGMAR1MC4R | |
| SCHEMBL3961457 | 0.79 | SMN1; SMN2 (0.66) | RECQLSMN1; SMN2TSHRSIGMAR1DRD2 | |
| SCHEMBL10745029 | 0.79 | MC4R (0.65) | CCR3SIGMAR1DRD4ACHEMC4R | |
| SCHEMBL4797625 | 0.79 | SIGMAR1 (0.69) | RECQLSMN1; SMN2TSHRCCR3SIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070208036-A1 | Arylalkanes, arylalkenes and aryl-azaalkanes, pharmaceutical compositions containing these compounds and processes for preparing them | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2007-09-06 | — | — | US | disclosed |
| US-7230001-B1 | Arylalkane, arylalkene and aryl azaalkane, medicaments containing said compounds and method for the production thereof | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2007-06-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070208036-A1 | Arylalkanes, arylalkenes and aryl-azaalkanes, pharmaceutical compositions containing these compounds and processes for preparing them | ARRB1, NPY1R, ADRB3 | RECQL 3091/4885SMN1; SMN2 3515/4885TSHR 395/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.